11. March 2021 | Corporate News

Marinomed Biotech AG Enrolls First Patients in Phase II Clinical Trial of Tacrosolv to Treat Allergic Rhinoconjunctivitis (Hay Fever)

Press release

The full press release is available as download here:

Marinomed Biotech AG Enrolls First Patients in Phase II Clinical Trial of Tacrosolv to Treat Allergic Rhinoconjunctivitis (Hay Fever)
(136 KB)